Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Hypersensitivity and allergy

New drug could reduce symptoms of gluten exposure in people with coeliac disease

Research into a drug to reduce symptoms of inadvertent gluten exposure in people with coeliac disease has shown promising results.

Micrograph of the jejunum affected by coeliac disease

Source: Biophoto Associates / Science Photo Library

Researchers randomly assigned patients on a gluten-free diet to six injections of a monoclonal antibody, called AMG 714, over a ten-week period and found significant reductions in intestinal inflammation

A monoclonal antibody could help reduce symptoms of coeliac disease in people with the condition who are accidentally exposed to gluten, according to study findings presented at Digestive Disease Week, held in Washington DC on 2–5 June 2018[1].

Researchers randomly assigned patients on a gluten-free diet to six injections of the drug, known as AMG 714, at a dose of either 150mg or 300mg, or a placebo over a ten-week period. From week 2 to 2 weeks after treatment (week 12), the patients then underwent a gluten exposure challenge.

While there was no significant difference in the primary end point — a measurement of damage to the villous lining of the intestine — between treatment groups, there were significant reductions in inflammation and symptoms in response to gluten consumption.

Patients receiving the highest dose of AMG 714 had no clinically active disease at week 12 and also had a significant improvement in self-reported outcomes, compared with placebo.

The researchers said there was a need for treatments for coeliac disease, as even on a gluten-free diet people are often inadvertently exposed to gluten.

“AMG 714 merits development as an adjunct to [gluten-free diet] in non-responsive coeliac disease,” they concluded.

Citation: Clinical Pharmacist DOI: 10.1211/CP.2018.20205174

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Dale and Appelbe's Pharmacy and Medicines Law

    Dale and Appelbe's Pharmacy and Medicines Law

    This new edition of Dale and Appelbe's Pharmacy and Medicines Law is the definitive guide to law and ethics for pharmacy practice in the UK. It covers law and professional regulation and is firmly established as the definitive student textbook and reference work on this subject in the UK. Fully updated to include changes to pharmacy laws and regulation.

    £57.00Buy now
  • Pharmacy Registration Assessment Questions 2

    Pharmacy Registration Assessment Questions 2

    Pharmacy Registration Assessment Questions 2 features more than 400 entirely new, closed book and calculation questions. It can be used in conjunction with the previous volume or on its own. All questions are in line with current GPhC guidance, enabling you to prepare for the pharmaceutical pre-registration exam with confidence.

    £35.00Buy now
  • Pharmacy Registration Assessment Questions

    Pharmacy Registration Assessment Questions

    Pharmacy Registration Assessment Questions features over 400 closed book and calculation questions. With the registration exam having gone through a complete transformation in 2016, this volume has been developed around the new General Pharmaceutical Council (GPhC) guidelines.

    £33.00Buy now
  • Foundation in Pharmacy Practice

    Foundation in Pharmacy Practice

    A practical and succinct overview of the principal pharmacy practice topics, for new pharmacy students.

    £33.00Buy now
  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Micrograph of the jejunum affected by coeliac disease

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.